

Reference:	FOI.20928.26
Subject:	Non-Small Cell Lung Cancer (NSCLC)
Date of Request:	3 July 2026

Requested:

How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy
- Osimertinib

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with all the information requested, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested for Chemotherapy and Radiotherapy, the UHB would need to undertake a manual trawl of the medical records of all patients that are receiving these therapies, to identify if they were receiving treatment for NSCLC and the stage of the cancer, or any information that would fulfil your request, as this is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable to individuals who have made a request under the FoIA, which can include assisting a requestor to further refine their request.

Unfortunately, the UHB is unable to provide advice on how you can refine your request further. This is due to the UHB still requiring a manual trawl of all Chemotherapy and Radiotherapy patient records to be undertaken, to identify information that may fulfil this part of your request.

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute

unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

The UHB provides within the table below, the number of early stage (non-metastatic or Stages 1-3) NSCLC patients that have been treated with the listed medications, during the period 1 April 2026 and 30 June 2026.

Medication	Number
Atezolizumab (Tecentriq)	*
Durvalumab (Imfinzi)	0
Nivolumab (Opdivo)	0
Pembrolizumab (Keytruda)	5
Chemotherapy	17
Radiotherapy	Section 12 exemption applied
Chemotherapy AND Radiotherapy	Section 12 exemption applied
Osimertinib	*